This barrier is unrelated to the end of the transition period, following the United Kingdom's departure from the EU.

Public ID: PID-RG5QQ9

Multi-Centre Clinical Trial Hurdles affecting UK exporters in Indonesia

in Indonesia

Trade barrier summary

UK firms perceive the Material Transfer Agreement (MTA) Decree No. 657 of 2009 to be a barrier to conducting international clinical research in Indonesia.
The MTA prohibits the import of biological samples for laboratory tests into Indonesia, unless a sample cannot be tested in Indonesia, or if importing a sample serves the interest of quality control, i.e. updating the standard diagnostic capabilities in Indonesia.
In Multi-country clinical studies, it is essential that key laboratory tests are measured in a single centralised laboratory; to eliminate variations in the results due to the differences between laboratories.
It can take several months to obtain an MTA from the Ministry of Health. Consequently, the number of clinical studies conducted by multinational companies significantly decreased after the introduction of the MTA decree and has never recovered.

Sectors affected

  • Healthcare services



Date reported

14 September 2020

Last updated

1 June 2022

Public ID


Back to search results

If a trade barrier is affecting your exports or investment from the UK, please let us know on report a trade barrier .

If you export goods you can check duties and customs procedures for your chosen market.